Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
about
Community-acquired pneumonia: identification and evaluation of nonrespondersClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsAntibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections.Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesUsing Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.Therapeutic drug monitoring for tomorrow.Approaches for dosage individualisation in critically ill patients.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Antimicrobial stewardship of β-lactams in intensive care units.Optimal design of perturbations for individual two-compartment pharmacokinetic analysis.Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.The use and risks of antibiotics in critically ill patients.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses.A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapyTherapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.The clinical relevance of plasma protein binding changes.UPLC-MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units.Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.Use of cryopoor plasma for albumin replacement and continuous antimicrobial infusion for treatment of septic peritonitis in a dog.[Strategies to avoid antibiotic resistance].Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
P2860
Q27002420-982DF756-907C-4F16-BD13-A1B35825DE06Q28551453-2B35298B-9ED7-4872-91F4-839AA6F0BB81Q30316322-D3B2B889-9E6E-4581-BE53-CFDA8F7618D7Q33552161-1F621501-C1AA-4E8E-AD9C-1A85ED4766FFQ33821972-A6E5D572-4336-4ACA-98E1-B00797965349Q34274190-D0AAE4BD-5607-45E0-8505-E822F07F1AF2Q34327857-D57C4C24-5600-4629-AD19-2D8A008335C0Q34490565-854E3D12-AE3D-4C17-AAC8-01AC8621F132Q34894900-70CD5DF9-85BC-44B9-B6D5-38FFF18A7300Q34923002-F3F4F3B8-71B6-4970-997B-B6B91852272CQ35617587-141137FC-3B9C-4358-86ED-6851FF53DB33Q35694058-F8FDC1C5-2543-4825-A8C6-7BDEE5CEEA0FQ35986250-57A369B9-A89F-4D95-9D7B-E6CFF3F1E629Q36242447-DEB0CFC3-1299-4AD7-9CC5-6E572342D57CQ36517624-3172F3FE-8AE1-490C-928C-6EA8A48CA7F6Q36760879-8D807159-8322-4008-93BB-58474099ACB6Q38103768-60607351-46B3-4D52-9049-FA650BFEB12DQ38125209-449781D6-B1BC-4A1A-8174-31BE6A28B01CQ38138835-88C086BF-E203-4511-97FE-787F4151CA53Q38198157-3F6E670A-35EA-4DB5-97C8-3740FB3BA6D9Q38275439-281BA13E-7F14-4203-8E24-C62578FE5D41Q38528292-F606F663-9868-4926-85FD-738F31FD32A0Q38705266-3C7B9569-E233-42A2-BDAC-DBC6C89365CEQ38767901-A19FD2E8-E0DA-496B-9418-384002960FDBQ38896040-D7FD94A6-E50C-4109-A613-B89960890AA1Q39376296-27E4B71B-D357-4F8C-81D5-4057C0048219Q39721085-70FD1D7D-477F-484C-A241-E1BCA05196EBQ40172540-9C74658E-4E3F-454F-9429-387B4B05A5EEQ41435865-6BCA0E4B-CC8E-446B-859C-C15897459364Q42236097-BF148FC3-5C68-410F-BC42-16CC17A27838Q43830944-C4843F9C-2F13-402D-9FD4-2CE6594E5C68Q48016535-B03414B0-0CA7-4E92-9674-244141EC9F55Q48144933-F4B2AB26-7D47-4B51-B46A-743241264A28Q51024819-723F9DD4-F96D-4B82-93FB-6511A98B838BQ52885133-0BC71F22-F700-4E73-A241-B02D83D8CA97Q54261873-594B547C-460C-462C-89F0-2064829136E6Q57237700-C49A61D8-3FF6-43C1-8E53-058E74615D70
P2860
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@ast
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@en
type
label
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@ast
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@en
prefLabel
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@ast
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@en
P2860
P50
P356
P1476
Does Beta-lactam Pharmacokinet ...... nitoring? A Systematic Review.
@en
P2093
Sandra L Peake
P2860
P2888
P356
10.1186/2110-5820-2-35
P577
2012-07-28T00:00:00Z
P5875
P6179
1020507376